A 27-year-old man had symptoms of hyperthyroidism and periodic paralysis. While hyperthyroid, his serum thyrotropin (TSH) level was inappropriately elevated at 6.4/iU/ml. The serum alpha subunit level was also elevated. MRimaging revealed a pituitary tumor and transsphenoidal adenomectomywas performed. Immunocytochemistry with an antibody directed against the beta-subunit of TSHrevealed a TSH-secreting tumor.
commondisease characterized by episodes of flaccid paralysis, usually accompanied by hypokalemia. The disorder occurs most frequently in Oriental men (1 , 2) in their second and third decades (3, 4) . Most reported cases are associated with Graves' disease (5) . Only a few cases have been described in patients with hyperthyroidism due to other diseases (6) (7) (8) . It is thought that pituitary tumors rarely secrete TSH, but this phenomenonhas been increasingly recognized as a cause of hyperthyroidism (9) . Wereport here the first case of hyperthyroidism due to a TSHsecreting pituitary tumor associated with periodic paralysis.
MATERIALS AND METHODS

Hormoneassays
Serum thyroxine (T^, 3, 5, 3'-triiodothyronine (T3), free T4 and thyroxine binding globulin (TBG) concentrations were measured by radioimmunoassay (RIA). Serum TSHwas measured with a highly sensitive immunoradiometricassay. The antithyroglobulin and antimicrosomal antibodies (TGHAand MCHA) were measured by a haemagglutination method using artificial gelatin particle carriers. AntiTSHreceptor antibody (TRAb) was measured by radioreceptor assay (10) . Serum concentration of the alpha-subunit of TSH(TSH-a) was measured by RIA (ll) using reagents kindly provided by the National Institutes of Diabetes, Digestive and Kidney Diseases (NIDDKD). The achilles reflex time was determined by kinemometry. The assay results as well as the normal ranges are shown in Table 1 normal, but serum creatine kinase was low.
PREOPERATIVE COURSE
The results of the thyroid function studies at the time of admission are shown in Table 1 . Serum total T4, T3 and free T4 concentrations were all elevated with an inappropriately elevated TSH level of 6.4 fj.U/m\. T uptake and serum TBGconcentration were norrr *1. The serum TSH-alevel was elevated and TSH-/TSH molar ratio (6.3) was higher than 1.0. The b sal metabolic rate (+10%) was in the high normai range and the achilles reflex time of 200 msec was in the hyperthyroid range. TGHA,MCHA and TRAb were negative. The thyroid 123I scan showed a slightly enlarged gland with diffuse increased uptake and an elevated RAIUof 53.3%. The results of the TRHstimulation test are shown in Fig. 1 . Administration of 500/ig TRHcaused no rise in TSH. Serum PRL levels showed a small response. The results of the endocrine studies of other hormones were as follows. The basal level of GHand its responses to both arginine and L-dopa stimulation were normal. The basal level of serum PRLwas normal and its response to sulpiride administration was slightly low (29.4 ng/ml, peak value). Both basal and LH-RH stimulated gonadotropin (LH and FSH) levels were normal. The basal level of ACTHwas normal. The effect of exogenous 1-T3 is shown in Table  2 . After 150//g/day of 1-T3 administration, serum T3 increased from 256 to 492 ng/dl. Serum TSH and RAIU decreased from 6.4 to 3.1^U/ml and from 53 to 26% , respectively, but complete suppression of neither TSH nor RAIUwas achieved. The BMR value increased slightly from +10% to + 12%. The mean pulse rate increased from 70 to 89 bpm.
HLAtyping showed the following antigens: A2, All, Bw46, Bw48, DRw8and DRw9. A C locus was not found. Roentgenograms of the skull demonstrated enlargement of the sella turcica with a double floor. Magnetic resonance imaging (MRI) of the brain revealed a pituitary tumor of 15 x 20 mm in the sellar region with no destruction of the floor (Fig. 2) . The presumptive diagnosis of a TSHsecreting pituitary tumor was madeand the patient underwent surgery.
PATHOLOGICAL FINDINGS AND POSTOPERATIVE COURSE
In December 1988, transsphenoidal resection of the tumor was performed. Immunocytochemistry with an anti-beta-subunit of TSH antibody indicated that TSH immunoreactivity was present in the cytoplasm of adenoma cells (Fig. 3) . Incubation with anti-ACTH, anti-GH, anti-PRL, anti-FSH and anti-LHantibodies gave negative results.
After the operation, therapy with dexamethasone, 0.5 mg daily, and propranolol, 30 mg daily, was started. Four weeks after the operation the serum T4 was 21.6 /ag/dl and T3 was 252 ng/dl. TSH remained inappropriately elevated at 2.76 fi\J/ml. A repeat MRI of the brain two months after the operation showed the suspected adenoma remnant with the pituitary stalk shifted leftward. After a single oral dose of 2.5 mg bromocriptine, TSH levels were effectively decreased (Fig. 4) .
Therefore, the patient was given bromocriptine 7.5 mgdaily. Twoweeks later, thyroid function tests the serum a subunit level was elevated and the molar ratio of a/TSH was more than 1.0 (12). Serum TSH levels ranged from 1.7 to 480^iU/ml (12) and about one fourth had normal levels (15). In contrast, in most patients with selective pituitary resistance to thyroid hormones, TRHadministration resulted in rapid TSH secretion. In these patients, the serum a subunit level was not elevated and the molar ratio of a/TSH was less than 1.0 (12).
In the present case, the serum TSH level did not change with TRH, but was partially suppressed after T3 administration. The serum a subunit level was elevated and the molar ratio of a/TSH was 6.3. These biochemical data strongly suggest that this patient has a TSH-secreting tumor. Furthermore, MRimaging revealed a pituitary tumor, and the final diagnosis of a TSH-secreting tumor was confirmed by immunohistochemistry.
Hyperthyroidism due to a pituitary TSH-secreting tumor has characteristic clinical features (9) . The hyperthyroidism seen is usually mild. The thyroid gland, though variable, is often minimally enlarged. Graves' ophthalmopathy is absent in most cases. There is usually poor correlation between the degree of TSH elevation and the increase in thyroid hormone levels. The present case had all these The incidence of TPP amongthyrotoxic patients is reported to be 1.8% (1), 1.9% (3) and 8.8% (2 
